FDA Approves DAYBUE — Acadia Pharmaceuticals Inc.

# FDA Approves Acadia Pharmaceuticals' DAYBUE (trofinetide) for Rare Neurological Disorder Acadia Pharmaceuticals Inc. received FDA approval for DAYBUE (trofinetide), an oral treatment marking a significant commercial opportunity in the rare disease market and potentially expanding the company's portfolio beyond its existing psychiatric medication franchise. The approval positions Acadia to capture demand in a previously underserved patient population, though market uptake will depend on reimbursement coverage and physician adoption rates for this novel indication.